All Trials

ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated, measurable advanced/metastatic gastric, gastroesophageal junction, or distal esophageal adenocarcinoma that is HER2-negative and PD-L1 ≥1 are randomized to platinum/fluoropyrimidine chemotherapy (FOLFOX or CAPOX) plus pumitamig (BNT327/PM8002; bispecific anti–PD-L1/anti–VEGF-A checkpoint/anti-angiogenic antibody) versus the standard nivolumab (anti–PD-1) plus the same chemotherapy backbone. Key exclusions include untreated CNS metastases, recent major cardiovascular/thromboembolic events or uncontrolled hypertension, major coagulation disorders, recent GI perforation/fistula, and recent major surgery/trauma.

ClinicalTrials.gov ID: NCT07221149

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated advanced/unresectable or metastatic clear cell RCC (all IMDC risk groups; KPS ≥70; measurable disease) are randomized to fianlimab (anti–LAG-3) plus cemiplimab (PD-1 inhibitor) with or without ipilimumab (CTLA-4 inhibitor) versus standard ipilimumab plus nivolumab (PD-1 inhibitor, with nivolumab maintenance). The trial evaluates ORR and safety of LAG-3/PD-1 dual blockade (± CTLA-4) as first-line immunotherapy in this population.

ClinicalTrials.gov ID: NCT07188896

A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally advanced or metastatic non-squamous NSCLC (adenocarcinoma only), ECOG 0–1, measurable disease, and radiographic progression after their most recent therapy (with or without actionable genomic alterations; stable treated brain metastases allowed). Single-arm treatment is rinatabart sesutecan monotherapy q3 weeks, an FRα-targeting antibody–drug conjugate delivering a topoisomerase I inhibitor payload, continued until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT07288177

AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable stage IIIB/IIIC or metastatic stage IV squamous or non-squamous NSCLC without actionable driver alterations, systemic-therapy naïve for advanced disease (ECOG 0–1, measurable disease, known PD-L1 status), are randomized to PF-08634404/SSGJ-707 (investigational bispecific antibody targeting PD-1 and VEGF) plus histology-appropriate platinum-based chemotherapy followed by maintenance, versus pembrolizumab plus the same chemotherapy followed by standard maintenance. Primary outcomes compare overall survival and centrally reviewed PFS between regimens.

ClinicalTrials.gov ID: NCT07222566

A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of IBI363 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic squamous NSCLC (ECOG 0–1, RECIST-measurable) whose disease progressed during or within 6 months after prior anti–PD-1/PD-L1 therapy and after platinum-doublet chemotherapy are randomized 1:1 to IBI363 vs docetaxel. IBI363 is a PD-1–blocking bispecific fusion protein delivering a CD25-biased IL-2 mutein to stimulate tumor-reactive T/NK cells, given IV Q3W after a priming dose, compared with standard docetaxel 75 mg/m² IV Q3W.

ClinicalTrials.gov ID: NCT07217301

TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with previously untreated stage IIIB/C or IV NSCLC not amenable to curative therapy (ECOG 0–1; PD-L1 unselected; excluding EGFR-sensitizing mutations, ALK fusions, or ROS1 translocations; treated/stable brain metastases allowed) are randomized to add eftilagimod alfa (soluble LAG-3–Ig fusion protein, MHC class II agonist that activates antigen-presenting cells to enhance T-cell priming) or placebo to standard first-line pembrolizumab plus histology-appropriate platinum-doublet chemotherapy. Primary outcomes are overall survival and RECIST 1.1 progression-free survival.

ClinicalTrials.gov ID: NCT06726265

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with high-grade serous epithelial ovarian/fallopian tube/primary peritoneal cancer with radiographic platinum-resistant relapse (progression >3 to ≤6 months after last platinum) after 1–3 prior systemic lines undergo central FRα testing and are enrolled into FRα-high or FRα-low cohorts. Patients are randomized to AZD5335 (torvutatug samrotecan), an FRα/FOLR1-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor payload, versus mirvetuximab soravtansine in FRα-high disease or versus investigator’s choice single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan) in FRα-low disease.

ClinicalTrials.gov ID: NCT07218809

A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant, RECIST-measurable high-grade serous ovarian/fallopian tube/primary peritoneal cancer with CCNE1 (Cyclin E1) overexpression after 1–4 prior systemic lines (with prior bevacizumab and, if FRα-positive, prior mirvetuximab expected) are randomized to INCB123667, an oral selective CDK2 inhibitor targeting Cyclin E1–driven cell-cycle progression, versus investigator’s choice standard single-agent chemotherapy.

ClinicalTrials.gov ID: NCT07214779

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent platinum-sensitive high-grade serous or endometrioid ovarian/fallopian tube/primary peritoneal cancer who have completed second-line platinum doublet chemotherapy and have CR/NED, PR, or stable disease (and BRCA-mut/HRD+ patients must have previously received 1L PARP maintenance) are randomized within 8 weeks to maintenance rinatabart sesutecan plus standard-of-care (bevacizumab maintenance if chosen or observation) versus standard-of-care alone. Rinatabart sesutecan is an FRα-targeted antibody–drug conjugate that delivers an intracellular topoisomerase I inhibitor payload to FRα-expressing tumor cells.

ClinicalTrials.gov ID: NCT07225270

A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma (TRIDENT)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed (within 6 weeks), previously untreated metastatic pancreatic adenocarcinoma with measurable disease (RECIST 1.1) and ECOG 0–1 (excluding prior gemcitabine/nab-paclitaxel exposure for PDAC, significant neuropathy, chronic steroid need, active HIV/HBV/HCV, uncontrolled CNS mets, and known BRCA mutations) receive first-line nab-paclitaxel plus gemcitabine. Relacorilant, an investigational selective glucocorticoid receptor antagonist/modulator aimed at reducing cortisol-driven GR signaling and taxane resistance, is given orally 150 mg daily for 3 days around each chemotherapy dose in 28-day cycles until progression or toxicity.

ClinicalTrials.gov ID: NCT07259317